CRISPR Therapeutics’ CMO Naimish Patel Reports Stock Purchase
The transaction triggered repayment obligations under SEC rules after a subsequent sale within six months.
January 29, 2026
Naimish Patel, Chief Medical Officer at CRISPR Therapeutics, Purchases Shares, Commits to Short-Swing Profit Repayment
On April 3, 2025, Naimish Patel, Chief Medical Officer at CRISPR Therapeutics, purchased 1,508 common shares at $32.96 each. The transaction was executed under a Rule 10b5-1 trading plan, which is designed to structure stock purchases and sales in advance.
Roughly eight weeks later, the same number of shares were sold at $35.94 apiece. That sale, dated May 29, 2025, was automatic—it occurred under a “sell to cover” clause in an RSU agreement that vested on the same day.
Because the sale took place within six months of the initial purchase, it triggered a short-swing profit under SEC Rule 16(b), which requires insiders to return any gains from matching buy and sell transactions within that window.
Patel has agreed to pay back the full amount of the short-swing profit— $4,493.84 —to CRISPR Therapeutics. This repayment reflects the amount earned between the initial purchase and the later sale, based on the reported prices.
His direct ownership now includes the 1,508 shares acquired in the April transaction. The company disclosed the update in a standard Form 4 filing dated January 27, 2026.
Context for Investors
This sequence of events follows routine disclosure and compliance protocols for public company insiders. It also shows how structured equity plans like RSU awards and pre-scheduled trades can intersect with regulatory timing rules.
The end result: the company receives a reimbursement, and investors get a clear look at insider activity.
Share
Read More Articles
